Metabolism Disorder TRIZ Cases

DPP-4 inhibitors improve glycemic control while reducing adverse effects of conventional antidiabetic agents to accelerate wound healing.

A pharmaceutical composition containing a DPP-4 inhibitor reduces osteoblast differentiation to prevent aortic valve calcification.

Segmented humanized antibody constructs target malignant B and T cells via clonal lineage markers, reducing immune reactions against normal cells.

A phosphorus-binding composition controls blood phosphorus levels in periparturient animals.

Reutericyclin reverses antibiotic-induced weight gain by preserving non-pathological intestinal flora.

Selective lipophilic protein denaturation enables high-purity fractionation of 7S and 11S soybean globulins without salt addition.

A PCV2 antigen immunogenic composition administered to sub-clinically infected pigs reduces viral load and growth impairment.

Antibodies targeting pro-myostatin block activation, resolving toxicity issues from mature myostatin blockade.

Targeted amino acid modifications in glucagon and GLP-1 co-agonist peptides extend blood serum half-life while maintaining biophysical stability.

Multi-step chromatographic process purifies recombinant human heparan-N-sulfatase using sequential anionic exchange and hydrophobic interaction columns.

Cycloheptapeptides kill tumor cells and reduce body weight while minimizing side effects.

Segmented tube feed packages cycle diverse whole food components to resolve metabolic disturbances and immune compromise in long-term feeding.

IgG4 Fc fusion extends half-life and reduces proteolytic degradation, resolving metabolic disorder treatment limitations.

Novel GLP-1 derivatives incorporate specific amino acid substitutions and negatively charged moieties to enhance receptor binding affinity.

Replacing disulfide bonds with diselenide bonds in genomically recoded organisms prevents bond breakage in blood serum, extending protein half-life.

Administering a microbe composition with AF12, Helicobacter, or Odoribacter bacteria resolves antibiotic resistance while treating metabolic syndrome.

Neutral pH insulin formulations with hyaluronidase reduce catheter failure and skin irritation while extending infusion duration.

A composite pharmaceutical composition inhibits alpha-glucosidase activity through synergistic chemical interaction.

A wearable injection device detects low blood glucose and automatically administers glucagon to treat hypoglycemia.

Isolating c-kit positive pancreatic stem cells for tissue repair applications.

Segmented enteric coating and cationic nanoparticles protect insulin from gastric acid while opening intestinal tight junctions for absorption.

A segmented enzymatic hydrolysis process produces specific polypeptides that activate insulin receptors and enhance adipocyte metabolism.

Enzymatic hydrolysis resolves low survival rates by breaking down proteins into digestible peptides, reducing deformities.

Peptidomimetics combine glucagon antagonism with GLP-1 agonism via unnatural amino acids.

An oat-derived peptide targets calcium-sensing receptors to activate Gq pathways, addressing safety concerns in obesity treatments.

FKBP11 peptide compositions reduce blood glucose levels while avoiding side effects associated with conventional oral diabetes medications.

A choline and niacin composition reduces LDL cholesterol levels through methylation support.

A pharmaceutical composition combining rhodiola extract with alpha-Glycerophosphocholine to restrain body fat formation.

Cardiac targeting peptides deliver molecular cargoes to heart tissue, reducing reperfusion injury.

Soluble fiber component increases flowability and cold water solubility of powdered beverage composition, eliminating mechanical mixing requirements.

Spray drying and agglomeration create salt-stabilized enzyme particles that reduce dust generation while maintaining uniform distribution in animal feed.

Proline iminopeptidase catalyzes dipeptide formation to eliminate D-amino acid impurities and meet pharmaceutical standards.

Low-dose abscisic acid improves glucose tolerance without excessive insulin secretion or beta-cell depletion.

GalNAc-conjugated RNAi agents inhibit HAO1 enzyme activity, reducing urinary oxalate production without requiring liver transplantation.

Fully human monoclonal antibodies bind PCSK9 with enhanced affinity at acidic pH, reducing LDL cholesterol by 65-80% without affecting HDL levels.

Modified GLP-1 analogues enhance metabolic effects while reducing adverse side effects.

Composite lipophenol structures resolve the lipid solubility trade-off to enhance bioavailability and efficacy against neurodegenerative oxidative stress.

Combining metformin with branched-chain amino acids suppresses lactic acidosis risk while maintaining hypoglycemic efficacy in diabetic patients.

Ecklonia cava extract inhibits vascular smooth muscle cell migration to treat atherosclerosis without hepatotoxicity.

Fatty acid-modified GIP peptides bind albumin to overcome DPP-IV inactivation and fibril formation, extending plasma half-life for metabolic disease treatment.

Reducing sodium chloride content below 0.17 mg/mL eliminates complex buffering requirements while maintaining chemical stability across a broad pH range.

Broken lactic acid bacteria cells release intracellular components to lower cholesterol and visceral fat levels.

Extrusion processing fortifies legumes with yeast autolysate and chromium, resolving hard-to-cook issues while ensuring uniform expansion.

A composition of bergamot, berberine phospholipids, Ipomea batata, and olive extracts inhibits cholesterol synthesis.

Segmented CHIR priming followed by Activin A accelerates SOX17 peak expression, resolving delayed induction in conventional protocols.

MccJ25 peptide reduces hyperglycemia and improves insulin sensitivity without metformin side effects.

Weight-based aldosterone antagonist dosing reduces mortality and morbidity risks without inducing hyperkalemia in non-human mammals.

Segmented GDF15-Fc constructs address treatment complexity by simultaneously improving lipid tolerance, lowering triglyceride levels, and reducing food intake.